# Module 07 leadership defense

## Q01. What exact council decision does this package support?
Answer: It supports whether the fictional clinical performance council should accept the curriculum package and what revision work may proceed before any test review.
Evidence: `leadership-summary.md` and `recommendation-and-alternatives.md`.
Practical consequence: The package may proceed to final curriculum review.
Limit: No clinical test or workflow change is authorized.

## Q02. Which evidence is strongest, and which uncertainty most narrows it?
Answer: The bounded evening-shift roomed-to-clinician constraint is the strongest operational finding. The absence of a qualifying scenario and missing local safety, access, workforce, and feasibility evidence most narrows action.
Evidence: `evidence/checkpoint1/candidate/module-03/outputs/process-stage-comparison.csv` and `evidence/checkpoint2/candidate/module-06/outputs/feasibility-screen.csv`.
Practical consequence: Leadership can focus revision on the accepted constraint without assuming a solution.
Limit: Root cause and an effective redesign are not established.

## Q03. Why do the signals and bottleneck evidence not establish root cause?
Answer: Control-chart and run-chart rules identify time patterns that merit review. The stage comparison localizes a bounded constraint, but it does not isolate staffing, schedule, acuity, workflow, or another mechanism.
Evidence: `evidence/checkpoint1/candidate/module-03/outputs/signal-audit.csv` and `evidence/checkpoint1/candidate/module-03/outputs/bottleneck-reconciliation.csv`.
Practical consequence: The council must investigate mechanisms before proposing a cause-specific redesign.
Limit: A signal is not a generated cause and a stage difference is not a causal estimate.

## Q04. What does the forecast support, and why does it not define staffing?
Answer: It supports a 21-shift planning view with Week 53 point 876.924084 and empirical range 805.136639 to 970.733035 arrivals. Its errors and difficult folds bound use.
Evidence: `evidence/checkpoint2/candidate/module-04/outputs/forecast-findings.json` and `evidence/checkpoint2/candidate/module-04/outputs/error-summary.csv`.
Practical consequence: Leaders can plan sensitivity around demand.
Limit: Capacity conversion lacks local role coverage and safe-staffing evidence, and Little's Law equilibrium is not established.

## Q05. Why did no scenario qualify, and which failed result matters most?
Answer: Every option misses at least one conjunctive rule. S02's 86.671644-minute median-wait worsening under slower-service stress is the clearest stop signal.
Evidence: `evidence/checkpoint2/candidate/module-05/outputs/scenario-findings.json` and `evidence/checkpoint2/candidate/module-05/outputs/sensitivity-review.csv`.
Practical consequence: No current option becomes a test protocol.
Limit: The least unfavorable option cannot be selected after the fact.

## Q06. What do the four feasibility dispositions require next?
Answer: Retain S00 as the monitoring baseline, revise S01 and S03 through new contracts, and keep S02 stopped in its current form.
Evidence: `evidence/checkpoint2/candidate/module-06/outputs/feasibility-screen.csv`.
Practical consequence: Only missing-evidence and redesign work may proceed.
Limit: A disposition does not grant implementation authority.

## Q07. Which safety, return, access, and workforce evidence remains unavailable or unsupported?
Answer: Safety outcome, return within 72 hours, and workforce interruption or perceived-load baseline are prospectively unavailable. Target-window language and mobility comparisons are unsupported.
Evidence: `evidence/checkpoint2/candidate/module-06/outputs/monitoring-measures.csv` and `evidence/checkpoint1/candidate/module-03/outputs/subgroup-window-support.csv`.
Practical consequence: The revision plan must include governed prospective collection and support rules.
Limit: Unavailable or unsupported evidence cannot be treated as zero, favorable, safe, or absent burden.

## Q08. What do the monitoring and escalation rules authorize and prohibit?
Answer: They authorize human investigation, pause review, immediate clinical review, interpretability review, and baseline collection. They retain no-change monitoring as fallback.
Evidence: `monitoring-measures.csv` and `escalation-fallback-rules.csv`.
Practical consequence: Owners and response routes are explicit before any future protocol review.
Limit: The rules create zero automatic actions and do not start a test.

## Q09. Why does the ML challenger not supersede the transparent forecast?
Answer: Replacement requires all eight rules. R01 observes 0.731788 arrivals per shift of MAE improvement against a required 0.750000, so seven passing rules are insufficient.
Evidence: `evidence/checkpoint2/candidate/module-06/outputs/decision-change.csv`.
Practical consequence: Seasonal exponential smoothing remains the planning method.
Limit: Rounding, retuning, another model, or a moved threshold cannot repair the accepted decision.

## Q10. Who may benefit, carry burden, be excluded, or face risk?
Answer: Patients may experience delay, abandonment, access barriers, or routing risk. Staff may carry coverage, interruption, handoff, documentation, and monitoring work. High-acuity and support-needing patients require specific safeguards.
Evidence: `people-equity-safety-workforce.md`.
Practical consequence: Clinical, access, safety, and workforce owners must close the named conditions.
Limit: Synthetic and simulated evidence does not establish real benefit, inequity, safety, burden, or staffing need.

## Q11. How will frontline staff receive the decision and raise disagreement without blame?
Answer: The frontline brief states no redesign is selected, explains no-change monitoring, and routes safety, burden, access, workflow, and disagreement concerns to named owners.
Evidence: `frontline-brief.md` and `disagreement-record.md`.
Practical consequence: Staff concerns remain decision evidence rather than noncompliance.
Limit: Silence is not agreement and raising a concern does not trigger an automatic action.

## Q12. Who owns revision, review, pause, referral, stop, and restart decisions?
Answer: The clinical performance council is accountable. Named clinical, operations, safety, access, workforce, measurement, forecasting, ML, and frontline roles are responsible or consulted for their domains.
Evidence: `stakeholder-roles.csv`, `conditions-register.csv`, and `escalation-fallback-rules.csv`.
Practical consequence: Each open condition and decision route has an owner.
Limit: The learner, analyst, agent, dashboard, and model do not hold clinical authority.

## Q13. What did an agent contribute, and how was it checked?
Answer: The agent helped structure, assemble, and validate the package. Material facts were checked against exact accepted paths, nested validators, independent calculations already in the releases, and mutation tests.
Evidence: `ai-use.md`, `reproducibility-check.md`, and `responsible-claims-audit.md`.
Practical consequence: Agent assistance remains visible and reviewable.
Limit: Agent output is not evidence or independent human review.

## Q14. Why can the curriculum package pass while the recommendation remains revise before testing?
Answer: Package quality measures whether the evidence, judgment, communication, ownership, limits, and defense are complete. A clinical recommendation asks whether the evidence supports action. This package accurately concludes that it does not yet support a test.
Evidence: `component-score.csv`, `gate-results.csv`, and `progression-decision.md`.
Practical consequence: Checkpoint 03 may review the package and score without authorizing action.
Limit: Curriculum acceptance never grants clinical, staffing, testing, implementation, scoring, or deployment authority.
